Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, and Others), Drug Class [Plasma-derived Coagulation Factor Concentrates (Factor VIII, Factor IX, Factor for Von Willebrand Disease, and Activated Prothrombin Complex Concentrates), Recombinant Coagulation Factor Concentrates (Factor VIII, Factor for Von Willebrand Disease, and Factor IX), Desmopressin, Antifibrinolytics, Fibrin Sealants, and Others)] – Global Opportunity Analysis and Industry Forecast, 2022-2029
Download PDF Sample Report: https://www.alliedmarketresearch.com/request-sample/3577
Bleeding disorder refers to a condition that disrupts the process of coagulation of blood by preventing the formation of blood clots in hemophilic patients or patients with other bleeding disorders. Most of these bleeding disorders are inherited but some are acquired due to liver diseases, side effects of certain medications, low red blood cell count, vitamin K deficiency and others. The global bleeding disorders treatment market is expected to witness rapid growth during the forecast period due to increase in the number of people suffering from liver diseases, anemia, and other blood coagulation disorders.
The global bleeding disorder market is segmented based on type, drug class, and region. On the basis of type, it is classified into hemophilia A, hemophilia B, Von Willebrand disease, and others. Based on drug, it is categorized into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants, and others.
Key Benefits
- The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis of the industry from 2017 to 2023 to enable the stakeholders to capitalize on the prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled and their strategies have been analyzed thoroughly to understand the competitive outlook of the global market.
- Extensive analysis by product elucidates the use of various medicines for the treatment of hemophilia, clotting factor deficiency, and Von Willebrand disease.
Bleeding Disorders Treatment Market Key Segments:
By Type
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Others
By Drug Class
- Plasma-derived Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Factor for Von Willebrand Disease
- Activated Prothrombin Complex Concentrate
- Recombinant Coagulation Factor Concentrates
- Factor VIII
- Factor for Von Willebrand Disease
- Factor IX
- Desmopressin
- Antifibrinolytics
- Fibrin Sealants
- Others
Key Market Players
- Novo Nordisk
- Bayer AG
- Baxter International Inc.
- Alnylam Pharmaceuticals, Inc.
- Pfizer, Inc.
- Xenetic Biosciences, Inc.
- Bristol-Myers Squibb Company
- Sanofi
- Amgen, Inc.
- Janssen Global Services, LLC.
For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/3577
Other Healthcare Reports
Lateral Flow Assays MarketAbout Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.